Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H25N5O2 |
| Molecular Weight | 319.402 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C2=C(NC(=N2)C3(N)CCCC3)C(=O)N(CCC)C1=O
InChI
InChIKey=UFOBUCDTKQDDTN-UHFFFAOYSA-N
InChI=1S/C16H25N5O2/c1-3-9-20-12-11(13(22)21(10-4-2)15(20)23)18-14(19-12)16(17)7-5-6-8-16/h3-10,17H2,1-2H3,(H,18,19)
| Molecular Formula | C16H25N5O2 |
| Molecular Weight | 319.402 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://adisinsight.springer.com/drugs/800006420
Sources: https://adisinsight.springer.com/drugs/800006420
Midaxifylline, a potent and selective xanthine adenosine A1 receptor antagonist, was investigated for the treatment of Alzheimer's disease, cardiovascular disorders, kidney disorders, and major depressive disorder. However, all studies were discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:43 GMT 2025
by
admin
on
Mon Mar 31 18:22:43 GMT 2025
|
| Record UNII |
A937Z0MS6C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
A937Z0MS6C
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
151159-23-8
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
7641
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
3047747
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
SUB03288MIG
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
100000085962
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106736
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
DTXSID90164721
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
C66147
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|